Premature Ejaculation – Drugs In Development, 2024
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Premature Ejaculation – Drugs In Development, 2024 report and make more profitable business decisions.
Premature ejaculation (PE), also known as rapid ejaculation, is the most common type of sexual dysfunction in men. Ejaculation is controlled by the central nervous system. This happens when sexual stimulation and friction provide impulses that are delivered to the spinal cord and into the brain. The predisposing factors include erectile dysfunction, stress, and certain medications that influence the action of chemical messengers in the brain (psychotropics) may contribute to premature ejaculation. Treatment includes topical anesthetic creams and antidepressants.
The Premature Ejaculation drugs in development market research report provide comprehensive information on the therapeutics under development for Premature Ejaculation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Premature Ejaculation and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- Therapeutics in Development: Covering 7 molecules, with 6 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Premature Ejaculation therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Premature Ejaculation pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Premature Ejaculation treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
China Pharmaceutical UniversityCtcbio Inc
Dicot AB
Ixchelsis Ltd
Kanna Health Ltd
Plethora Solutions Holdings Plc
Wanbang Biopharmaceuticals Co Ltd
Zyvran Pharmaceuticals Inc